Frequently asked questions about the Hartford HealthCare Cancer Institute and Memorial Sloan Kettering Cancer Alliance
What is the Hartford HealthCare (HHC) Cancer Institute?
The HHC Cancer Institute was established to deliver high-quality, standardized, multidisciplinary and coordinated care to all HHC cancer patients, no matter where in the HHC system a patient receives care. As a system, HHC treats more than 5,000 new cancer cases annually. The institute model of care provides all the types of expert care a patient may need for his or her treatment and overall quality of life. This includes oncologists, nurses, pharmacists and other care givers.
What is Memorial Sloan Kettering (MSK)?
Memorial Sloan Kettering Cancer Center is the world’s oldest and largest private institution devoted to cancer prevention, treatment, research, and education. The National Cancer Institute has designated Memorial Sloan Kettering (MSK) as one of only 41 comprehensive cancer centers in the country, underscoring MSK’s multidisciplinary cancer research program, expert faculty, and state-of-the-art facilities. U.S. News & World Report ranked Memorial Sloan Kettering as one of the best hospitals for cancer care in the country and among the nation’s top pediatric hospitals for cancer in its 2013–2014 rankings.
What does the HHC Cancer Institute’s membership in the Alliance mean for patients?
HHC Cancer Institute patients now have increased access to world-renowned cancer care and unprecedented access to MSK clinical trials, which will be conducted on-site at Hartford Hospital and delivered by HHC Cancer Institute physicians. Clinical trials allow patients to receive the newest, most cutting-edge therapies and participate in advancing the care of future generations of cancer patients. Clinical trials are not just for patients with advanced disease. Expanding MSK’s clinical trials also speeds up data collection so that investigational therapies can become approved faster and made available to more patients.
Does the HHC Cancer Institute’s membership in the MSK Cancer Alliance mean that more HHC Cancer Institute patients will go to New York for care?
Because this Alliance will bring MSK standards of care to the HHC Cancer Institute, the Cancer Institute does not anticipate referring more patients to MSK. In most cases, HHC Cancer Institute patients will be treated by HHC Cancer Institute physicians using MSK standards of care. For treatments not offered by the HHC Cancer Institute, such as bone-marrow transplants, patients will have the option to go to MSK, as they do now.
When will the Cancer Alliance be in place?
The Alliance is in place and an MSK certification process is under way to ensure that the HHC Cancer Institute’s resources, capabilities and standards of care meet or exceed the most-recent and highest standards. Designated HHC Cancer Institute clinicians will observe new treatment techniques on-site at MSK in New York City. HHC Cancer Institute doctors will be integrated into MSK disease-management teams and actively participate in MSK clinical research. In addition to HHC Cancer Institute physicians, HHC Cancer Institute nurses, pharmacists, imaging experts and other care givers are undergoing training. The HHC Cancer Institute physician-in-chief will be on staff at both the HHC Cancer Institute and MSK, and an MSK researcher will be on-site at Hartford Hospital for two years.
Who do I go to for advanced care?
Your physician will provide direction for your care. Or, you may call 855.255.6181 to find a physician or specialist.
Download the FAQ Sheet
Click to download Frequently Asked Questions (FAQs)